Neurochemistry and Neuropharmacology of Schizophrenia

摘要: Introduction (F.A. Henn, Stony Brook, NY, and L.E. DeLisi, Bethesda, MD). 1. A historical perspective to the chemistry pharmacological treatment of schizophrenia (A. Carlsson, Goteborg, Sweden). 2. Two syndromes as one pole continuum psychosis: a conflict nature pathogen its genomic locus (T.J. Crow, Harrow, UK). 3. Neuroanatomical localization dopamine in brain spinal cord (O. Lindvall A. Bjorklund, Lund, 4. Pharmacology central dopaminergic neurons (M.E. Wolf, Detroit, MI, A.Y. Deutch R.H. Roth, New Haven, CT). 5. Central systems: neurophysiology electrophysiological pharmacology (B.S. Bunney S.R. Sesack, 6. Neuroleptic (J.M. Kane, Glen Oaks, NY). 7. treatments for Cott, N.M. Kurtz Wallingsord, 8. Norepinephrine metabolism (C.R. Lake, MD, J. Kleinman, Washington, DC, M.S. Kafka, Rockville, G. Ko, Seattle, WA, S. Smith Moore, M. Ziegler, San Diego, CA). 9. Indoleamines (S.M. Stahl, Harlow, UK, K. Wets, London, 10. The role neuroleptics (C.B. Nemeroff Bissette, Durham, NC). 11. Phospholipids prostaglandins (D. Brody, Wolkin Rotrosen, York, 12. neuroendocrinology (P. Powchik, B.M. Davis K.L. Davis, Bronx, 13. Endogenous hallucinogens other behavioral modifying factors (L.E. DeLisi R.J. Wyatt, 14. Pharmacological models (B. Angrist, 15. Tardive dyskinesia schizophrenic burnout: possible involvement cytotoxic free radicals (J.L. Cadet, J.B. Lohr D.V. Jeste, DC). 16. Neurological disorders (M. Trimble D. Rogers, 17. Genetic aspects biology (L.R. Goldin, E.S. Gershon, 18. Conclusion NY Subject index.